Bone marrow mesenchymal stem cells facilitate diabetic wound healing through the restoration of epidermal cell autophagy via the HIF-1 alpha/TGF-beta 1/SMAD pathway
机构:[1]Translational Medicine Collaborative Innovation Center, Shenzhen People’sHospital (The Second Clinical Medical College of Jinan Universit.The FirstAffiliated Hospital, Southern University of Science and Technology), Shenzhen518055, China深圳市人民医院深圳医学信息中心中国医科大学附属盛京医院[2]Guangdong Engineering Technology Research Centerof Stem Cell and Cell Therapy, Shenzhen Key Laboratory of Stem Cell Researchand Clinical Transformation, Shenzhen 518020, China[3]The First AffiliatedHospital, Jinan University, Guangzhou 510632, China[4]Chongqing Key Laboratoryof Traditional Chinese Medicine for Prevention and Cure of MetabolicDiseases, Chongqing Medical University, Chongqing 400016, China[5]Departmentof Plastic and Aesthetic Surgery, Jiangxi Maternal and Child HealthHospital, Nanchang 330006, China[6]Orthopaedic Trauma, Jiangxi ProvincialPeople’s Hospital (The First Affiliated Hospital of Nanchang Medical College),Nanchang 330006, Jiangxi, China[7]Department of Wound Repair, Instituteof Wound Repair and Regeneration Medicine, Southern University of Scienceand Technology Hospital, Southern University of Science and TechnologySchool of Medicine, Shenzhen 518055, China深圳市康宁医院深圳医学信息中心[8]Department of Burn and PlasticSurgery, Guangzhou First People’s Hospital, South China University of Technology,Guangzhou 510180, Guangdong, China
Background: The biological activity and regenerative medicine of bone marrow mesenchymal stem cells (BMSCs) have been focal topics in the broad fields of diabetic wound repair. However, the molecular mechanisms are still largely elusive for other cellular processes that are regulated during BMSC treatment. Our previous studies have shown that hypoxia is not only a typical pathological phenomenon of wounds but also exerts a vital regulatory effect on cellular bioactivity. In this study, the beneficial effects of hypoxic BMSCs on the cellular behaviors of epidermal cells and diabetic wound healing were investigated. Method: The viability and secretion ability of hypoxic BMSCs were detected. The autophagy, proliferation and migration of HaCaT cells cultured with hypoxic BMSCs-derived conditioned medium were assessed by estimating the expression of autophagy-related proteins, MTS, EdU proliferation and scratch assays. And the role of the SMAD signaling pathway during hypoxic BMSC-evoked HaCaT cell autophagy was explored through a series of in vitro gain- and loss-of-function experiments. Finally, the therapeutic effects of hypoxic BMSCs were evaluated using full-thickness cutaneous diabetic wound model. Results: First, we demonstrated that hypoxic conditions intensify HIF-1 alpha-mediated TGF-beta 1 secretion by BMSCs. Then, the further data revealed that BMSC-derived TGF-beta 1 was responsible for the activation of epidermal cell autophagy, which contributed to the induction of epidermal cell proliferation and migration. Here, the SMAD signaling pathway was identified as downstream of BMSC-derived TGF-beta 1 to regulate HaCaT cell autophagy. Moreover, the administration of BMSCs to diabetic wounds increased epidermal autophagy and the rate of re-epithelialization, leading to accelerated healing, and these effects were significantly attenuated, accompanied by the downregulation of Smad2 phosphorylation levels due to TGF-beta 1 interference in BMSCs. Conclusion: In this report, we present evidence that uncovers a previously unidentified role of hypoxic BMSCs in regulating epidermal cell autophagy. The findings demonstrate that BMSC-based treatment by restoring epidermal cell autophagy could be an attractive therapeutic strategy for diabetic wounds and that the process is mediated by the HIF-1 alpha/TGF-beta 1/SMAD pathway.
基金:
National Natural Science Foundation of China [82060350]; GuangDong Basic and Applied Basic Research Foundation [2021A1515011453, 2022A1515011380]; Industry-universityresearch Innovation Fund of Higher Education of China [2021JH028]
语种:
外文
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|2 区医学
小类|2 区细胞与组织工程2 区细胞生物学2 区医学:研究与实验
最新[2025]版:
大类|2 区医学
小类|2 区细胞与组织工程2 区细胞生物学2 区医学:研究与实验
JCR分区:
出版当年[2020]版:
Q1CELL & TISSUE ENGINEERINGQ1CELL BIOLOGYQ1MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1CELL & TISSUE ENGINEERINGQ1CELL BIOLOGYQ1MEDICINE, RESEARCH & EXPERIMENTAL
第一作者机构:[1]Translational Medicine Collaborative Innovation Center, Shenzhen People’sHospital (The Second Clinical Medical College of Jinan Universit.The FirstAffiliated Hospital, Southern University of Science and Technology), Shenzhen518055, China[2]Guangdong Engineering Technology Research Centerof Stem Cell and Cell Therapy, Shenzhen Key Laboratory of Stem Cell Researchand Clinical Transformation, Shenzhen 518020, China[3]The First AffiliatedHospital, Jinan University, Guangzhou 510632, China
共同第一作者:
通讯作者:
通讯机构:[1]Translational Medicine Collaborative Innovation Center, Shenzhen People’sHospital (The Second Clinical Medical College of Jinan Universit.The FirstAffiliated Hospital, Southern University of Science and Technology), Shenzhen518055, China[2]Guangdong Engineering Technology Research Centerof Stem Cell and Cell Therapy, Shenzhen Key Laboratory of Stem Cell Researchand Clinical Transformation, Shenzhen 518020, China
推荐引用方式(GB/T 7714):
Yan Shi,Shang Wang,Weiwei Zhang,et al.Bone marrow mesenchymal stem cells facilitate diabetic wound healing through the restoration of epidermal cell autophagy via the HIF-1 alpha/TGF-beta 1/SMAD pathway[J].STEM CELL RESEARCH & THERAPY.2022,13(1):doi:10.1186/s13287-022-02996-9.
APA:
Yan Shi,Shang Wang,Weiwei Zhang,Yihan Zhu,Zhiqiang Fan...&Ronghua Yang.(2022).Bone marrow mesenchymal stem cells facilitate diabetic wound healing through the restoration of epidermal cell autophagy via the HIF-1 alpha/TGF-beta 1/SMAD pathway.STEM CELL RESEARCH & THERAPY,13,(1)
MLA:
Yan Shi,et al."Bone marrow mesenchymal stem cells facilitate diabetic wound healing through the restoration of epidermal cell autophagy via the HIF-1 alpha/TGF-beta 1/SMAD pathway".STEM CELL RESEARCH & THERAPY 13..1(2022)